Ticker: IQV

IQVIA

Healthcare Healthcare Medical - Diagnostics & Research

Price 271.55

Reco Buy Potential 75 Risk 30 Updated 2026-10-27

Official website

Forecast impact

limited

Target +10.9% target fill 90.2%

Reaction D5 +2.37% · D10 +8.40% fresh confirmed · market trust

Impact Potential 0 · Risk 0 valid until 2026-11-13

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

IQVIA is a healthcare analytics and technology company that provides data, insights, and services to the life sciences industry. Its core offerings include advanced analytics, technology solutions, and contract research services. Major business segments encompass technology and analytics solutions, and contract research services, with primary revenue sources derived from pharmaceutical and biotech clients seeking to enhance their research and development processes.

Investment Profile

The investment profile of IQVIA suggests it may be more suitable for value investors, given its current market position and performance metrics. The stock exhibits characteristics that align with a cautious approach, reflecting potential for recovery but also notable risks. Investors should consider a medium to long-term horizon for potential stabilization.

Category: Healthcare Sector: Healthcare Industry: Medical - Diagnostics & Research Investment style: Growth Horizon: Long-term Company type: Blue Chip Company type: Market Leader

Fundamental metrics (experimental) Updated: 2026-10-26

EPS (TTM) — earnings per share for the last 12 months, $: 8.13
Revenue QoQ — quarter-over-quarter revenue growth: 5.2%
EPS surprise: 4.0%
20d volatility: 1.6%

AI recommendation changes

Date	Before	After	Reason
2026-07-29	Hold	Buy	Strong momentum and positive EPS surprise support growth outlook.
2026-07-15	Buy	Hold	Weak fundamentals and mixed momentum signal caution.
2026-07-07	Hold	Buy	Mixed performance; cautious outlook amid fundamental weakness.
2026-06-29	Sell	Hold	Recent momentum is positive, but fundamentals show weakness.
2026-06-09	Hold	Sell	Weak fundamentals and negative momentum raise concerns.
2026-05-30	Sell	Hold	Mixed momentum; fundamentals show weakness and high risk.
2026-05-16	Hold	Sell	Weak fundamentals and negative momentum indicate high risk.
2026-05-08	—	Hold	Weak fundamentals and high risk limit upside potential.
2026-05-05	Sell	Hold	Компания показывает умеренный рост выручки, но за последние 120 дней наблюдается значительное снижение цены акций. Рекомендуется удерживать позицию до прояснения ситуации на рынке.
2026-04-24	Hold	Sell	Компания демонстрирует значительное снижение цены акций за последние месяцы, что указывает на высокие риски. Несмотря на положительные показатели выручки, общая динамика и высокая волатильность вызывают опасения.
2026-03-25	Sell	Hold	Компания показывает смешанные результаты, с недавним падением цены акций и высоким уровнем риска. Устойчивый рост выручки и положительный сюрприз по EPS могут указывать на потенциал для восстановления.
2026-03-16	Hold	Sell	Компания показала значительное снижение за последние 60 дней, что указывает на высокие риски. Однако положительный рост выручки и EPS может свидетельствовать о потенциале для восстановления.
2026-03-01	Sell	Hold	Компания показывает положительную динамику за последние дни, но значительное падение за 20 и 60 дней вызывает опасения. Рекомендуется удерживать акции до более ясных сигналов о восстановлении.
2026-02-04	Hold	Sell	Компания показывает значительное снижение цены за короткий срок, что указывает на высокие риски. Отсутствие данных по EPS и другим ключевым показателям также вызывает опасения.
2026-01-30	Buy	Hold	Компания показывает стабильный рост за последние 120 дней, однако недавние колебания цен и отсутствие данных по EPS и дивидендам создают неопределенность. Рекомендуется удерживать акции до получения более ясной информаци
2026-01-27	Hold	Buy	Компания показывает стабильный рост за последние 120 дней, что свидетельствует о положительной динамике. Несмотря на отсутствие данных по EPS и дивидендам, высокаяMomentum и рост цены делают акцию привлекательной для инв
2026-01-25	Buy	Hold	Компания показывает положительную динамику на длительном горизонте, однако недавние колебания цен и отсутствие данных по EPS и дивидендам указывают на повышенные риски.
2026-01-23	Hold	Buy	Компания показывает положительную динамику на длительном горизонте, что указывает на рост. Несмотря на небольшие колебания в краткосрочной перспективе, долгосрочные показатели выглядят многообещающе.

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-10-14	Stifel Nicolaus	Target Raised	276 → 303	260.71
2026-10-07	Mizuho Securities	Target Raised	275 → 300	260.16
2026-10-07	Barclays	Target Raised	275 → 300	260.16
2026-09-30	UBS	Update	— → 345	269.19
2026-09-28	Truist Financial	Target Raised	300 → 329	270.37
2026-09-17	Morgan Stanley	Target Raised	240 → 270	268.82
2026-07-29	RBC Capital	Target Raised	221 → 247	246.03
2026-07-29	BMO Capital	Target Raised	210 → 270	249.51
2026-07-29	Robert W. Baird	Target Raised	252 → 287	243.31
2026-07-13	Mizuho Securities	Target Raised	215 → 230	207.85
2026-07-09	Deutsche Bank	Update	— → 240	208
2026-07-06	HSBC	Target Raised	210 → 240	206.42
2026-07-01	Robert W. Baird	Target Raised	230 → 249	193.22
2026-06-17	Morgan Stanley	Rating Downgraded	— → 200	179.17
2026-06-03	HSBC	Target Lowered	240 → 210	180.64
2026-05-07	Morgan Stanley	Target Lowered	240 → 225	179.31
2026-04-08	Evercore ISI	Target Lowered	225 → 185	172.54
2026-02-23	Mizuho Securities	Target Lowered	266 → 215	165.62
2026-02-19	Truist Financial	Target Lowered	290 → 245	165.64
2026-02-11	Morgan Stanley	Target Lowered	265 → 240	178.875
2026-02-06	UBS	Target Lowered	280 → 240	184.01
2026-02-06	BMO Capital	Target Lowered	260 → 250	184.75
2026-02-06	Stifel Nicolaus	Target Lowered	273 → 220	184.67
2026-02-06	Barclays	Target Lowered	230 → 210	180.96
2026-02-05	Evercore ISI	Target Lowered	— → 225	180.96

News Page 1 of 1

Analysts Ritholtz Wealth Management highlight Iqvia Holdings (IQV) as a strong performer with 79% gains since April low

10/22/2026, 08:39 AM investing review Analysts: analysts, Ritholtz healthcare IQVIA

Iqvia Holdings (IQV), a key player in the healthcare services sector, has seen its stock rise 79% since April, driven by its integration of AI technologies and strong earnings performance. As the company prepares to report its Q3 results, investors are closely watching its potential for continued growth in a rapidly evolving market.

Stocks Making Significant Moves Midday: Boeing, Amkor, Corning, Sandisk, Iqvia, and More

07/28/2026, 10:37 AM review Micron PayPal Boeing Amkor Technology Coca-Cola Royal Caribbean Sherwin-Williams Sandisk IQVIA Corning

Midday trading saw significant movements in various stocks, with Boeing and Iqvia reporting strong earnings, while Amkor and Corning faced declines due to disappointing guidance. These fluctuations reflect broader trends in the aerospace, semiconductor, and consumer goods sectors, impacting investor sentiment.

Analysts Truist Securities maintain buy rating for Amazon (AMZN) with price target of $320, indicating 38% upside ahead of earnings report

07/25/2026, 06:32 AM investing forecast Analysts: analysts, Truist internet Amazon IQVIA Vertiv

Next week, several major tech companies, including Amazon and Apple, are set to report earnings, with heightened expectations from analysts indicating strong momentum for these stocks, particularly in cloud services and healthcare technology.

Analysts highlight IQVIA (IQV) and Danaher (DHR) as leading biotech stocks poised for recovery

07/14/2026, 09:38 AM investing review Analysts: analysts biotech healthcare IQVIA Vertex Pharmaceuticals Danaher

The biotechnology sector, which has faced significant challenges in recent years, is showing signs of recovery, presenting potential investment opportunities in companies like IQVIA, Danaher, and Vertex Pharmaceuticals. This shift is driven by stabilizing funding conditions, increased clinical trial activity, and the need for pharmaceutical companies to innovate as patent expirations loom.

IQVIA’s AI Platform Enhances Competitive Advantage in Drug Development Amid Growing Demand

06/24/2026, 11:36 AM investing growth healthcare IQVIA

IQVIA is poised for significant growth as it leverages its extensive healthcare data and new AI capabilities, despite currently being undervalued in the market. The company's recent guidance increase and record backlog highlight its strong position in the drug development sector.